An observational study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM), sponsored by Bayer. Recruiting at 17 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Bayer · Observational
Austria, Belgium, Croatia, Denmark, Estonia, Finland, Italy, Latvia, Lithuania, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a serious and life-threatening condition where a protein called transthyretin (TTR) misfolds and builds up as amyloid fibrils in the heart muscle. This buildup causes the heart to become stiff, leading to restrictive cardiomyopathy and progressive heart failure. There are two forms of ATTR-CM: a hereditary or 'variant' form (vATTR-CM) caused by a gene mutation, and a 'wild-type' form (wtATTR-CM) which is associated with aging. Because its symptoms can be similar to other heart conditions, ATTR-CM is often diagnosed late. However, recent advances in medical imaging are helping doctors to identify the disease earlier. Acoramidis is a new medication designed to treat ATTR-CM. It works by stabilizing the TTR protein, preventing it from misfolding and forming the harmful amyloid deposits. Acoramidis has been shown to be effective and safe in a major clinical trial (the ATTRibute-CM study), which led to its approval for use in both the United States and Europe. While clinical trials provide valuable information, data on how a new medicine performs in everyday clinical practice is also very important. This type of information is called real-world evidence. Currently, there is limited real-world information about the use of acoramidis. This study, called ACO-REAL, is an observational study, which means researchers will observe patients who are receiving acoramidis as part of their normal clinical care, without introducing any experimental interventions. The study will take place in approximately 20 European countries and aims to enroll up to 2,000 adults who have been diagnosed with either wild-type or variant ATTR-CM and are starting treatment with acoramidis. This includes patients who have not been treated for ATTR-CM before, as well as those who have been treated with other therapies. The main goals of the study are to understand the characteristics of patients being treated with acoramidis and to document how the treatment is used in routine medical practice. The study will also collect information on the safety of acoramidis. Furthermore, researchers will assess how the treatment affects patients' heart function, their functional capacity (such as their ability to walk), their overall health status, and their quality of life. The study will also track how often patients need to use healthcare resources like hospitals or emergency rooms. This information will help to improve the understanding and management of ATTR-CM in a real-world setting, ultimately aiming to optimize care for patients with this progressive disease.
82 studies on the registry are indexed under Amyloidosis, Hereditary, Transthyretin-Related; 28 are open to participants now.
This study's planned enrollment of 2,000 is above the median of 100 across 40 observational studies indexed under Amyloidosis, Hereditary, Transthyretin-Related.
Browse Amyloidosis, Hereditary, Transthyretin-Related studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with an established diagnosis of either wild-type or variant Transthyretin Amyloid Cardiomyopathy (ATTR-CM) who are eligible for treatment with acoramidis based on the clinical decision of the investigator, made independently of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participation in an trial with interventions outside of routine clinical practice, except for participation in potential sub-studies related to this observational study. Please note: In addition to this observational study, separate sub-studies may be conducted to collect additional data. Participation in these sub-studies is voluntary and will be governed by separate protocols and processes. The main observational study does not include interventional procedures beyond routine clinical practice.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) initiating treatment with acoramidis in routine clinical practice.
Drug: Acoramidis (356 mg film-coated tablets)
Follow clinical practice/administration.
Also known as: BEYONTTRA
Patient demographic characteristics: age
Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.
Time frame: Baseline (Initial study visit)
Patient demographic characteristics: sex
Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.
Time frame: Baseline (Initial study visit)
Patient demographic characteristics: race
Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.
Time frame: Baseline (Initial study visit)
Patient demographic characteristics: height
Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.
Time frame: Baseline (Initial study visit)
Patient demographic characteristics: weight
Demographic characteristics at the first documented regular visit in the study, referred to as the initial study visit.
Time frame: Baseline (Initial study visit)
Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Type
ATTR-CM type: mixed phenotype (yes/no)
Time frame: Baseline up to 15 months
Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Genetic status
ATTR-CM type: genetic status (mutation / wild type; if mutation: genotype and zygosity)
Time frame: Baseline up to 15 months
Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis
ATTR-CM diagnosis (year of diagnosis)
Time frame: Baseline up to 15 months
Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Setting of Diagnosis
ATTR-CM setting of diagnosis: (endomyocardial biopsy / non-invasive / both, NYHA classification at diagnosis)
Time frame: Baseline up to 15 months
Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Manifestations
ATTR-CM manifestations (type)
Time frame: Baseline up to 15 months
Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) -relevant comorbidities
ATTR-CM-relevant comorbidities (type)
Time frame: Baseline up to 15 months
Clinical Characteristics: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) -relevant procedures
Prior and concomitant ATTR-CM-relevant procedures (type)
Time frame: Baseline up to 15 months
Treatment Patterns with Acoramidis: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) -related medications
Previously administered ATTR-CM-related medications within the past 12 months before initial visit (name)
Time frame: Baseline (assessment within the past 12 months prior to initiation)
Treatment Patterns with Acoramidis: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) concomitant medications
Concomitant medications administered alongside acoramidis (name)
Time frame: Baseline up to 15 months
Treatment Patterns with Acoramidis: Initiation
Acoramidis initiation (date)
Time frame: Baseline up to 15 months
Treatment Patterns with Acoramidis: Initiation after a different therapy
Acoramidis initiation (if patient is switching from a different therapy: reason for switch)
Time frame: Baseline up to 15 months
Treatment Patterns with Acoramidis: discontinuation
Acoramidis discontinuation (reason)
Time frame: Baseline up to 15 months
Treatment Patterns with Acoramidis: interruption
Acoramidis interruption (reason)
Time frame: Baseline up to 15 months
Treatment Patterns with Acoramidis: prescription / refills
Acoramidis prescriptions/refills since the last visit or telephone contact (duration of time from initiation to discontinuation of therapy)
Time frame: Baseline up to 15 months
Incidence of Adverse Events
Adverse events (AEs) documentation
Time frame: From acoramidis initiation up to end of observation (approximately 12-15 months).
Incidence of Serious Adverse Events
Serious Adverse events (SAEs) documentation
Time frame: From acoramidis initiation up to end of observation (approximately 12-15 months).
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Started Oct 2025 (actual). Primary completion is estimated for Apr 2028, 30 months after the start.
Of 25 observational studies under Amyloidosis, Hereditary, Transthyretin-Related, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 97. This study's planned 30 months is below that.
Completion moved once since we started tracking on Sep 25, 2026: Jul 2028 → Apr 2028, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Austria, Belgium, Croatia, Denmark, Estonia, Finland, Italy, Latvia, Lithuania, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, United Kingdom
Austria, Belgium, Croatia, Denmark, Estonia, Finland, Italy, Latvia, Lithuania, Norway, Portugal, Slovenia, Spain, Sweden, Switzerland, United Kingdom
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloidosis, Hereditary, Transthyretin-Related →